We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, M... NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others. Show more
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported that it received a notice (the “Notice) on April 4, 2024 from...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.006 | 1.44578313253 | 0.415 | 0.4485 | 0.4 | 74835 | 0.42502543 | CS |
4 | -0.0041 | -0.96447894613 | 0.4251 | 0.4653 | 0.39 | 83052 | 0.42882492 | CS |
12 | -0.2706 | -39.1266628109 | 0.6916 | 1.15 | 0.39 | 246666 | 0.75665882 | CS |
26 | -0.249 | -37.1641791045 | 0.67 | 1.51 | 0.39 | 294614 | 0.8575642 | CS |
52 | -2.325 | -84.6686088857 | 2.746 | 4.8 | 0.39 | 814061 | 1.91997743 | CS |
156 | -114.179 | -99.6326352531 | 114.6 | 132 | 0.39 | 403768 | 14.09804553 | CS |
260 | -89.579 | -99.5322222222 | 90 | 257.8 | 0.39 | 332434 | 49.38851066 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions